Brief: Cognition Therapeutics reports Q2 results
09/08/2022 12:50
Aug 9 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS REPORTS SECOND QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
* Q2 LOSS PER SHARE $0.25
* CASH AND CASH EQUIVALENTS ON JUNE 30, 2022 WAS
APPROXIMATELY
$45.8 MILLION
* ESTIMATES THAT IT HAS SUFFICIENT CASH TO FUND OPERATIONS
AND
CAPITAL EXPENDITURES INTO Q4 OF 2023
Source text for Eikon: ID:nGNX4VVmBM
Further company coverage: CGTX.O
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB